Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metabolic syndrome may worsen cognitive performance in patients with schizophrenia

Publish date:: July 6, 2020

Key clinical point: A defective metabolic state in patients with schizophrenia may impair neurocognitive performance.

Major finding: Schizophrenia patients with normal metabolism had significantly higher symbol coding scores (P = .012) and spatial span test scores (P = .018) compared with those with metabolic syndrome.

Study details: A total of 158 patients with schizophrenia who were receiving antipsychotic medications for ≥1 year were enrolled in the study.

Disclosures: This study was funded by the Guangdong Science and Technology Planning Project. The authors declared no conflicts of interest.

Citation:

Chen S et al. Psychiatry Res. 2020 Apr 15. doi: 10.1016/j.psychres.2020.112941.

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Schizophrenia & Other Psychotic Disorders

Risk factors for QTc prolongation during amisulpride therapy in schizophrenia,

Schizophrenia: Reinitiating clozapine can be considered in patients who have previously discontinued it,

Elevated IL-18 levels in patients with schizophrenia,

Schizophrenia: Antipsychotic choice may influence driving-related cognitive performance,

Treatment-resistant schizophrenia: Is slower-than-recommended titration of clozapine beneficial?,